Research report
Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression

https://doi.org/10.1016/S0165-0327(97)00168-7Get rights and content
Under a Creative Commons license
open archive

Abstract

Background: Testosterone replacement therapy is an effective treatment of some depressive symptoms in hypogonadal men, and may be an effective augmentation treatment for SSRI-refractory major depression in such men. Methods: We treated five depressed men who had low testosterone levels and had not responded to an adequate SSRI trial with 400 mg testosterone replacement biweekly for 8 weeks. Four patients underwent single-blind placebo discontinuation. Patients were assessed at baseline and biweekly thereafter using the Hamilton Depression Rating Scale (HAM-D) and the Endicott Quality of Life Enjoyment and Satisfaction Scale (Q-LES-Q). Results: Patients' mean age was 40 years, and mean testosterone level 277 ng/dl. All had a rapid and dramatic recovery from major depression following testosterone augmentation: mean 21-item HAM-D decreased from 19.2 to 7.2 by week 2, and to 4.0 by week 8; mean Q-LES-Q increased from 45% to 68%. Three of four subjects who underwent discontinuation of testosterone under single-blind placebo treatment began to relapse. Conclusion: Testosterone replacement therapy may be an effective treatment of depressive symptoms in some men, and warrants further research.

Keywords

Testosterone
Major depression
Androgens
Refractory depression
Psychoendocrine
Open clinical trial

Cited by (0)